Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Floorless Preferred Stock/Debenture -- Ignore unavailable to you. Want to Upgrade?

To: xcr600 who wrote (1313)	7/8/2001 12:49:45 AM
From: jjs_ynot	Read Replies (2) \| Respond to of 1438

Looks like a classic floorless: biz.yahoo.com RANCHO SANTA MARGARITA, Calif., July 6 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU - news) announces that on June 22, 2001, a $500,000 convertible promissory note, and the related accrued interest, were converted into the Company's common stock. On June 29, 2001, Trinity USA raised an additional $500,000 with the same institutional investor, RoyCap Inc., through the issuance of a convertible promissory note. The note bears interest at 8% and has a term of one year. The note is convertible at a conversion price equal to the lesser of $4.00 or 80% of the average closing bid price of the common stock for the ten consecutive trading days preceding the conversion date. The note is convertible at the option of Trinity USA upon certain events. On the date of conversion, Trinity USA will issue to RoyCap Inc. a warrant to purchase the number of shares of Trinity USA's common stock equal to aggregate the number of shares of common stock issued upon conversion of this note. The warrant will have an exercise price equal to $4.00 per share and have a term of five years from its date of issuance.

To: xcr600 who wrote (1313)	7/8/2001 10:55:33 AM
From: xcr600	Respond to of 1438

Ontario, California - June 25, 2000 - LifePoint, Inc. (LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced the closing of an institutional equity private placement offering pursuant to Regulation D of the Securities Act of 1933. Gross proceeds of the offering were $11 million. The Series C 10% Convertible Preferred Stock is convertible into Common Stock at $3.50 per share and includes warrant coverage. Well Fargo Van Kasper acted as the placement agent for the offering. ---- During the quarter ended March 31, 2001, the Company sold the following securities without registering them under the Securities Act: Private Placement On March 29, 2001, the Company sold an aggregate of 75,000 shares of a newly designated series of the Company's Preferred Stock, $.001 par value (the "Preferred Stock"), designated the Series B 20% Cumulative Convertible Preferred Stock (the "Series B Preferred Stock"). Each share of the Series B Preferred Stock is convertible into ten shares of the Common Stock. The Series B Preferred Stock is senior to any other series of the Preferred Stock hereafter designated and the Common Stock with respect to dividends, upon redemption and upon liquidation, except as may be consented to by the holders of at least 66.67% of the then outstanding shares of the Series B Preferred Stock. The Series B Preferred Stock provides for a cumulative annual dividend on each outstanding share at a rate of 20% per share paid annually in shares of the Series B Preferred Stock for the first three years outstanding, thereafter paid at a rate of 6% annually payable, at the Company's option, in cash or shares of the Common Stock 10kwizard.com